{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:04:51Z","timestamp":1792623891780,"version":"4.5.0"},"reference-count":129,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2025,7,3]]},"DOI":"10.1080\/14656566.2025.2519690","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T07:06:21Z","timestamp":1749971181000},"page":"1205-1220","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Tackling multidrug-resistant Gram-negative infections in children globally: current therapeutic options and perspectives"],"prefix":"10.1080","volume":"26","author":[{"given":"Lorenzo","family":"Chiusaroli","sequence":"first","affiliation":[{"name":"University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Tripiciano","sequence":"additional","affiliation":[{"name":"Bambino Ges\u00f9 Children\u2019s Hospital","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Liberati","sequence":"additional","affiliation":[{"name":"University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marica","family":"De Pieri","sequence":"additional","affiliation":[{"name":"University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Brigadoi","sequence":"additional","affiliation":[{"name":"University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Don\u00e0","sequence":"additional","affiliation":[{"name":"University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"WHO. Antimicrobial resistance global report on surveillance. 2014."},{"key":"e_1_3_5_4_1","unstructured":"WHO. WHO bacterial priority pathogens list 2024. 2024 [cited 2025 Apr 16]."},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1660772"},{"key":"e_1_3_5_6_1","unstructured":"WHO. Shortages stockouts and scarcity [internet]. 2018. Available from: www.accesstomedicinefoundation.org"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002381"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12020261"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.09.013"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.05.018"},{"key":"e_1_3_5_11_1","unstructured":"Medicines Agency E. Human medicines evaluation division list of nationally authorised medicinal products active substance: fosfomycin (IV formulation) [Internet]. 2017. Available from: www.ema.europa.eu\/contact"},{"key":"e_1_3_5_12_1","volume-title":"Fosfomycin tromethamine \u2013 oral products","author":"FDA","unstructured":"FDA. Fosfomycin tromethamine \u2013 oral products. https:\/\/www.fda.gov\/drugs\/development-resources\/fosfomycin-tromethamine-oral-products"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11111458"},{"key":"e_1_3_5_14_1","unstructured":"Traunm\u00fc Ller F Popovic M Konz K-H et al. A reappraisal of Current dosing strategies for intravenous fosfomycin in children and neonates."},{"key":"e_1_3_5_15_1","volume-title":"Fosfomycin for injection","author":"IVOZFOTM","unstructured":"IVOZFOTM. Fosfomycin for injection. https:\/\/veritypharma.com\/sites\/default\/files\/2022-05\/IVOZFO\u2122-PM-01May2019_final.pdf"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad428"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv147"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw212"},{"key":"e_1_3_5_19_1","unstructured":"Nitrofurantoin FDA. [Internet]. [cited 2025 Apr 2]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020064s019lbl.pdf"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R352"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/8755122518755402"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2010.506189"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106344"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1153-z"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1039\/C5MD00344J"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/20469047.2017.1408738"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03464-14"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002120"},{"key":"e_1_3_5_29_1","unstructured":"Liu X Smits A Wang Y et al. Impact of Disease on amikacin pharmacokinetics and dosing in children [Internet]. 2018. Available from: www.drug-monitoring.com"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00737-21"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1086\/429323"},{"key":"e_1_3_5_32_1","unstructured":"EUCAST. Colistin breakpoints guidance document 2022 background [Internet]. 2022. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Guidance_docu"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1559817"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11081088"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx522"},{"key":"e_1_3_5_36_1","unstructured":"EMA Colistin [Internet]. [cited 2025 Apr 2]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/polymyxin-containing-medicines"},{"key":"e_1_3_5_37_1","unstructured":"Coly-Mycin\u00ae M parenteral (colistimethate for injection USP) [Internet]. Available from: https:\/\/www.fda.gov\/drugsatfda"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.06.052"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00002-21"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-2706"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2005.05.007"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-022-00513-2"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad257"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3170-3178.2003"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph13110333"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1358"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.3109\/07357909809032892"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.10.044"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.11.007"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01813-17"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00021-21"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2019.04.002"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw243"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0902-x"},{"key":"e_1_3_5_56_1","unstructured":"European Medicines Agency (EMA). Zavicefta INN-ceftazidime\/avibactam [Internet]. Available from: www.ema.europa.eu\/contact"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00862-16"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002392"},{"key":"e_1_3_5_59_1","doi-asserted-by":"crossref","unstructured":"Bradley JS Roilides E England; Richard. Safety and efficacy of ceftazidime-avibactam in neonates and young infants with bacterial infections: results from a phase 2a 2-part open-label non-randomized multicenter trial [Internet]. 2023. Available from: https:\/\/academic.oup.com\/ofid\/article\/10\/Supplement_2\/ofad500.2473\/7448215 et al.","DOI":"10.1093\/ofid\/ofad500.2473"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000003716"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy280"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00296-10"},{"key":"e_1_3_5_63_1","unstructured":"Zerbaxa EMA [Internet]. [cited 2025 Apr 3]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zerbaxa"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002170"},{"key":"e_1_3_5_65_1","unstructured":"EMA. Zerbaxa INN-ceftolozane\/tazobactam [Internet]. 2018. Available from: www.ema.europa.eu"},{"key":"e_1_3_5_66_1","unstructured":"Safety and pharmacokinetics of ceftolozane\/tazobactam in pediatric participants with nosocomial pneumonia. NCT04223752 [Internet]. [cited 2025 Apr 3]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04223752?cond=NCT04223752&rank=1"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa049"},{"key":"e_1_3_5_68_1","unstructured":"Ceftolozane\/tazobactam continuous infusion for infective exacerbations of cystic fibrosis and Bronchiectasis [Internet]. [cited 2025 Apr 3]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06035055?cond=Ceftolozane%2F%E2%80%8BTazobactam%20Continuous%20Infusion%20for%20Infective%20Exacerbations%20of%20Cystic%20Fibrosis%20and%20Bronchiectasis&rank=1"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24815"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2020.1756775"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00567-17"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00843-15"},{"key":"e_1_3_5_73_1","unstructured":"EMA. Vaborem [Internet]. [cited 2025 Apr 19]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaborem"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2187"},{"key":"e_1_3_5_75_1","unstructured":"A study to assess how vaborem\u00ae is taking up in the body and tolerated in paediatric patients with complicated urinary tract infection [Internet]. [cited 2025 Apr 3]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06828848?cond=meropenem%2Fvaborbactam&rank=6"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.07.073"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-023-02864-3"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2334"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piaf004"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020929988"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15040463"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11060723"},{"key":"e_1_3_5_83_1","unstructured":"Cefiderocol Injection [Internet]. [cited 2025 Apr 3]. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/cefiderocol-injection"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01872-19"},{"key":"e_1_3_5_85_1","unstructured":"A study to assess the safety tolerability and pharmacokinetics of cefiderocol in hospitalized pediatric participants [Internet]. [cited 2025 Apr 3]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04215991?cond=cefiderocol&page=2&rank=13&tab=table"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac248"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2023.104794"},{"issue":"1","key":"e_1_3_5_89_1","first-page":"11","article-title":"Extended spectrum beta-lactamases: definition, classification and epidemiology","volume":"17","author":"Ghafourian S","year":"2014","unstructured":"Ghafourian S, Sadeghifard N, Soheili S, et al. Extended spectrum beta-lactamases: definition, classification and epidemiology. Curr Issues Mol Biol. 2014;17(1):11\u201322.","journal-title":"Curr Issues Mol Biol"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12010169"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12163"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1479"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2024.08.002"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S314241"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106727"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00791-z"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/ped.12845"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz173"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.1999.tb00721.x"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-023-04715-5"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-024-02447-y"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy12050142"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2021.11.007"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0851-9"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05206-8"},{"key":"e_1_3_5_106_1","unstructured":"European Centre for Disease Prevention and Control (ECDC). Surveillance of antimicrobial resistance in Europe 2023 data: executive summary [Internet]. 2024 [cited 2025 Apr 16]. Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-resistance-europe-2023-data-executive-summary"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-015-0510-9"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad688"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbac029"},{"key":"e_1_3_5_110_1","volume-title":"EMBLAEVO","author":"European Medicines Agency","year":"2024","unstructured":"European Medicines Agency. EMBLAEVO. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/emblaveo"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu069"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12050796"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13111017"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2011.04.005"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2018.11.013"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S174876"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02365-12"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2782"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz668"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105891"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62220-0"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30796-9"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac078"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.02.2011.3807"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111367"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.1515"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.00987.x"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30099-9"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00065-22"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.24015\/JAPM.2018.0072"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2025.2519690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T22:55:39Z","timestamp":1758063339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2025.2519690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":129,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,7,3]]}},"alternative-id":["10.1080\/14656566.2025.2519690"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2025.2519690","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-04-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}